Team
Dr. Erich Platzer
Advisor
.svg)
Dr. Erich Platzer has been a key member of MTIP's Board from its inception and served in this role until August 2024. His contributions were integral throughout his tenure. Dr. Platzer continues to serve MTIP as an Advisor and currently serves on the boards of MTIP's portfolio companies Coramaze and Nitinotes.
Dr. Erich Platzer has been active in private equity investments for the last 25 years. Since the last ten years, he is an active business angel investor with lead roles in multiple investments. From 2001 until 2015, he has been Co-Founder and Investment Advisor of the private equity firm HBM BioVentures, now called HBM Healthcare Investments. During this time, he has held multiple board roles, including as chairman of various public and private biotech and medtech companies in the US and Europe. Prior to that, he spent 10 years in product development and marketing at Roche, where he last served as therapeutic area head of oncology, responsible for various strategic corporate partnerships.
Additionally, Dr Platzer has 12 years’ experience in academic medicine and research and was one of two co-founders and key members of the team at Memorial Sloan-Kettering Cancer Center that purified human G-CSF in 1983 (recombinant: Neupogen®), which currently has annual sales of more than USD 5 billion (including its pegylated form). Dr. Platzer has an MD from the Medical School of the University of Erlangen, where he also received his MD/PhD (habilitation qualification). Next to his board positions in Coramaze and Nitinotes, he is currently chairman of publicly traded Vivoryon Therapeutics NV, as well as private company LMD (Léman Micro Devices). He is also a board member of Aptose Biosciences Inc, a public company, and Panavance Therapeutics, a privately-held firm.
Involved in:
Languages:
.svg)
